CorMedix (CRMD) Q1 2026 earnings review
Strong Q1 Masks an Implied Second-Half Profitability Cliff
CorMedix delivered massive YoY growth, with Q1 revenue jumping 226% to $127.4M on the back of DefenCath penetration and the Melinta portfolio acquisition. Net income of $38.6M and Adjusted EBITDA of $70.0M reflect peak profitability levels. Management confidently raised FY26 guidance for both top and bottom lines. However, a deeper look reveals vulnerability: $9.0M of DefenCath's revenue was a one-time accounting benefit, meaning underlying sequential sales actually dipped. More concerning, capturing $70M in Q1 EBITDA against a raised FY guidance midpoint of $125M implies a severe profit deceleration for the rest of the year as the July TDAPA pricing cliff for DefenCath approaches.
🐂 Bull Case
Positive Phase III ReSPECT data for REZZAYO in prophylaxis gives CorMedix a clear path to a multi-billion dollar market. With an sNDA filing set for H2 2026, the company is securing its next major growth driver ahead of DefenCath's pricing compression.
Management increased FY26 Net Revenue guidance to $325-$345M and Adjusted EBITDA to $115-$135M, signaling confidence in Melinta's base cash flows and near-term DefenCath LDO utilization.
🐻 Bear Case
Reported DefenCath sales were $97.5M, but excluding a $9.0M favorable allowance adjustment, underlying sales were $88.5M—a sequential deceleration from $91.2M in Q4 2025.
Generating $70M of Adjusted EBITDA in Q1 leaves just $55M for the remaining three quarters (based on the $125M guidance midpoint). This implies a steep drop in H2 profitability as DefenCath transitions off peak TDAPA reimbursement.
⚖️ Verdict: ⚪
Neutral. The company is executing flawlessly on clinical trials and near-term commercialization, but the stock is staring down a known catalyst: a structural decline in DefenCath margins starting in July 2026. Investors should weigh the 2027 REZZAYO launch against the impending 2026 cash flow contraction.
Key Themes
DefenCath's Sequential Deceleration
A major red flag is buried in the DefenCath top line. While reported sales grew to $97.5M, $9.0M of this was a non-recurring favorable change in sales allowance estimates. Stripping this out, core DefenCath sales were ~$88.5M, decelerating sequentially from $91.2M in Q4 2025. This suggests LDO onboarding growth may have plateaued ahead of the TDAPA pricing transition.
REZZAYO Clinical Win Paves Way for 2027
CorMedix successfully de-risked its most important pipeline asset. The positive Phase III topline results for REZZAYO (prophylaxis of invasive fungal diseases) allows the company to file an sNDA in H2 2026. This transitions REZZAYO from a pipeline hope to a tangible 2027 revenue catalyst in a massive total addressable market.
Operating Expenses Surging Post-Acquisition
Total operating expenses surged 139% YoY to $41.5M. The increase is driven by the Melinta integration: G&A jumped 124% to $21.7M, and S&M climbed 180% to $12.5M. While CorMedix's current peak-level gross margins can absorb this bloat, strict cost controls will be required when DefenCath pricing compresses later this year.
Melinta Portfolio Adds Necessary Ballast
The acquired Melinta assets contributed $29.9M in Q1, representing typical first-quarter purchasing patterns for anti-infectives. While this represents a sequential drop from $37.4M in Q4 2025, it acts as a stable cash generator that limits downside risk and diversifies the company away from being a single-product story.
Other KPIs
Up from $144.8 million at the end of 2025. This robust liquidity profile allows management to fund R&D for the TPN and pediatric studies internally, execute share repurchases, and prepare for the REZZAYO commercial launch without needing near-term dilutive equity financing.
Accelerating dramatically YoY from $23.6 million in Q1 2025, demonstrating the massive cash generation capability of DefenCath under current TDAPA pricing. Adjustments primarily excluded $10.5 million in depreciation/amortization and $4.6 million in stock-based compensation.
Guidance
Accelerating vs prior guidance. Management raised the target from $300-$320M. With Q1 already delivering $127.4M, the remaining three quarters only need to average ~$69M to hit the midpoint. This implies management is baking in a sharp drop in H2 revenue corresponding with DefenCath's reimbursement transition.
Accelerating vs prior guidance of $100-$125M, but implies a severe deceleration for the rest of the year. With $70M printed in Q1, the midpoint of the new guidance ($125M) leaves only $55M for the next three quarters—an average of just ~$18.3M per quarter. This explicitly maps out the margin collapse expected in H2.
Key Questions
Underlying DefenCath Volume Plateau
Excluding the $9M allowance change, DefenCath sales declined slightly quarter-over-quarter. Has patient penetration at your core LDOs peaked under the current contract structures, or was there an inventory timing element at play?
Implied Q2-Q4 EBITDA Margin Contraction
The raised FY26 EBITDA guidance implies an average of ~$18M per quarter for the rest of the year, down drastically from $70M in Q1. How much of this forecasted drop is driven by post-July pricing compression versus anticipated SG&A ramp for the REZZAYO launch?
TDAPA Contract Renewals
With the July 1 TDAPA transition rapidly approaching, have you finalized post-TDAPA bundled add-on contracts with your primary LDOs, and what specific pricing compression should investors model for H2?